A new study shows experimental nose drops can restore memory and boost neuron growth in mice, offering a promising new path for treating cognitive decline and Alzheimer’s disease.
What Happened in the Study
Researchers at the University of Sydney tested nose drops containing mRNA in lipid nanoparticles on aged mice—18 months old, a model for human aging.
The mRNA carried instructions for nasal cells to produce brain-derived neurotrophic factor (BDNF), a protein vital for neuron survival and memory.
After treatment, the mice showed memory improvements matching those of young mice in tests.
Brain scans revealed 2.4 times more doublecortin-positive cells—markers of new neuron growth—especially in the hippocampus, key for learning and memory.
How the Method Works
BDNF supports neuron health, strengthens connections, and helps neurons survive.
Levels drop in Alzheimer’s, contributing to memory loss.
Traditional nasal sprays deliver BDNF, but it breaks down quickly in the nasal lining.
This method uses mRNA to make BDNF inside the body. The protein is produced over several days—up to four days in lab tests.
That means one drop can provide long-lasting effects without needing frequent reapplication.
Results in Alzheimer’s Mouse Model
Another group of mice had Alzheimer’s-like symptoms, including amyloid plaques and memory issues.
After treatment, memory improved and new neuron markers increased in the hippocampus.
Importantly, amyloid plaque levels did not decrease. The therapy does not clear plaques.

Instead, it strengthens existing neurons and their connections—offering a new way to improve brain function.
Why This Matters
Most Alzheimer’s treatments have focused on removing amyloid plaques.
But clinical trials show such treatments rarely improve real-world memory or daily function.
This method supports neuron health, which may help patients maintain or even improve cognition, even with existing disease.
Future versions could produce other brain-supporting proteins like NGF or GDNF, expanding use to other neurodegenerative conditions.
Limitations and Challenges
The study used only mice. Human noses and immune systems differ significantly from mice.
Before human trials, safety and effectiveness must be tested in larger animals.
Dr. Greg Neely, lead researcher, says human trials could begin in two years, if preclinical studies succeed.
Regulators will also need to confirm mRNA stability, immune response, and possible side effects before approval.
Still, this research marks a major step toward non-invasive, scalable treatments for cognitive decline.
The findings are published in the journal Advanced Science.
For more on this research, see the original source at sciencealert.com.
Sources & further reading
Featured image: Experimental Nose Drops Restored Fading Memory And Boosted Neuron Growth In Mice. Via original publisher. Image source



